Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline and Prestige Brands report financial results in the wake of their OTC brands deal; Allegra boosts Sanofi’s consumer business; lower private label sales hit NBTY; USANA plots North American growth.
You may also be interested in...
Rapidly Growing Prestige Brands Still Positioned For OTC Pickups
The company says it successfully integrated the OTC portfolio acquired from GlaxoSmithKline and is using free cash flow to trim its debt load in the wake of the debt-financed $660 million deal. Prestige reported Q1 net sales up 54.7%, including 4.2% organic growth in OTC health care.
Rapidly Growing Prestige Brands Still Positioned For OTC Pickups
The company says it successfully integrated the OTC portfolio acquired from GlaxoSmithKline and is using free cash flow to trim its debt load in the wake of the debt-financed $660 million deal. Prestige reported Q1 net sales up 54.7%, including 4.2% organic growth in OTC health care.
Omega Pharma Acquires Six Glaxo OTC Brands, But Alli Lingers
Omega Pharma will pay $619 million for GSK’s Lactacyd feminine wash products, Abtei supplements, Solpadeine analgesics, Zantac antacid, Nytol sleep aids and the allergy drug Beconase. The deal is part of Glaxo’s plan to simplify its consumer business by selling 19 OTC brands.